
TMS is Transcranial Magnetic Stimulation therapy, a non-drug treatment for major depression. TMS uses focused magnetic pulses, similar to an MRI, to reignite dormant synapses in the brain and help your brain function the way it was meant to.
It is not a drug, “shock” therapy, or surgery. It is a safe, effective treatment for MDD without the common side effects of medication
There are specific areas in your brain that control mood. When synapses in those mood-regulating areas are underactive, connections are broken and depression can result. NeuroStar revitalizes those dormant synapses, “waking up” the brain to function as it was meant to.
Many NeuroStar patients start to see improvement within 2 to 3 weeks of treatment. That can include changes in mood, fewer days of depression, and increased desire to engage with other people more often. In fact, your friends and family may notice your results before you do!
Completing the full NeuroStar treatment course gives the best chance for delivering long-lasting relief from depression.
As with any therapy, completion is key. Completing the full 6-week course of NeuroStar treatment gives the best chance for delivering long lasting relief from depression.
If you have been diagnosed with MDD (Major Depressive Disorder), and have not experienced relief from antidepressants, NeuroStar may be right for you. NeuroStar is not a drug. It is not another form of shock therapy or surgery. And it has none of the common side effects associated with medications.
NeuroStar is an in-office treatment lasting as little as 19 minutes per daily session over the course of 6 weeks. Choose one of the options below and see if NeuroStar is right for you.
Over 5.9 million NeuroStar Advanced TMS treatments have been performed in over 162,000 patients.
A real-world study reported an 83% response rate. This means that 83% of patients that completed their NeuroStar treatment cycle saw measurable improvement in their depression symptoms.
The same real-world study reported a 62% remission rate. This means that 62% of patients that completed their NeuroStar treatment cycle likely wouldn’t be diagnosed with MDD if they were first being evaluated by their doctor.
